Physician
Foundation for Sickle Cell Disease Research
Foundation for Sickle Cell Disease Research was paid $1.97M by Medicaid between Jan 2020 and Nov 2024, across 43 billing codes. Its largest line is 96360, Intravenous infusion, hydration; initial, 31 minutes to 1 hour — 19% of everything it billed.
33Billing provider infoFOUNDATION FOR SICKLE CELL DISEASE RESEARCH
HOLLYWOOD, FL 33023
HOLLYWOOD, FL 33023
33aNPI1053720243assigned 08/12/2014
33bProvider typeInternal Medicine Physician
28Total paid$1.97M
24GClaims262,922
24DCodes billed43
24AFirst – last monthJan 2020 – Nov 2024
Compared with peers
Next to other Internal Medicine Physician providers in Florida
Rank by total paid#22 of 1,247
Median peer was paid$9K
This provider vs. median225×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 8,256 | $90K | |
| 2021 | 20,345 | $244K | |
| 2022 | 93,376 | $562K | |
| 2023 | 85,135 | $589K | |
| 2024incomplete | 55,810 | $487K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 19% | 7,179 | 967 | $375K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 15,321 | 1,783 | $293K |
| 96361 | Intravenous infusion, hydration; each additional hour | 13% | 17,288 | 1,801 | $249K |
| 93000 | 11% | 13,437 | 1,856 | $218K | |
| 96375 | Therapeutic injection; each additional sequential IV push | 9.1% | 18,616 | 1,853 | $180K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 5.9% | 17,037 | 1,796 | $117K |
| 85018 | 4.8% | 12,312 | 1,669 | $94K | |
| 82962 | 2.9% | 13,998 | 1,830 | $57K | |
| 81002 | 2.7% | 9,222 | 1,210 | $54K | |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 2.6% | 3,728 | 668 | $51K |
| 36415 | Collection of venous blood by venipuncture | 2.2% | 803 | 257 | $43K |
| J1170 | Injection, hydromorphone, up to 4 mg | 2.2% | 13,254 | 1,207 | $43K |
31 more codes
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 2.0% | 8,840 | $40K |
| 85048 | 1.3% | 10,753 | $26K | |
| 99215 | Doctor's office visit, returning patient (complex) | 1.2% | 1,031 | $24K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 4,379 | $18K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 13,438 | $13K |
| 81025 | <1% | 9,766 | $13K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,233 | $12K |
| 81003 | <1% | 8,643 | $11K | |
| 96376 | <1% | 1,303 | $8K | |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 609 | $7K |
| J7070 | Infusion, d5w, 1000 cc | <1% | 2,586 | $4K |
| 85027 | <1% | 3,269 | $4K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 2,782 | $4K |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 16,445 | $3K |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | <1% | 366 | $3K |
| 82948 | <1% | 3,368 | $3K | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 10,198 | $2K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 120 | $1K |
| J7060 | 5% dextrose/water (500 ml = 1 unit) | <1% | 2,040 | $806.23 |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 21 | $568.40 |
| 94010 | <1% | 52 | $383.44 | |
| 96127 | <1% | 439 | $244.00 | |
| 99491 | Ccm add 20min | <1% | 157 | $115.56 |
| J0895 | Injection, deferoxamine mesylate, 500 mg | <1% | 39 | $70.27 |
| 36416 | <1% | 12,641 | $50.90 | |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | <1% | 304 | $50.20 |
| J1171 | Injection, hydromorphone, 0.1 mg | <1% | 226 | $48.35 |
| A4301 | Implantable access total catheter, port/reservoir (e.g., venous, arterial, epidural, subarachnoid, peritoneal, etc.) | <1% | 5,565 | $13.48 |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 73 | $1.99 |
| 99072 | 0% | 15 | $0.00 | |
| G2064 | Comprehensive care management services for a single high-risk disease, e.g., principal care management, at least 30 minutes of physician or other qualified health care professional time per calendar month with the following elements: one complex chronic condition lasting at least 3 months, which is the focus of the care plan, the condition is of sufficient severity to place patient at risk of hospitalization or have been the cause of a recent hospitalization, the condition requires development or revision of disease-specific care plan, the condition requires frequent adjustments in the medication regimen, and/or the management of the condition is unusually complex due to comorbidities | 0% | 26 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBRONTE, LANETTA (PRESIDENT AND CEO)